Pharma — April 2023
-
Lundbeck når primære endepunkt i migræneforsøg i Hope-studie https://www.proinvestor.com/investornyt/970031/lundbeck-nar-primaere-endepunkt-i-migraeneforsog-i-hope-studie
-
Sydbank kalder Lundbecks migrænemiddel for spændende i stort migrænemarked
https://www.proinvestor.com/investornyt/970057/sydbank-kalder-lundbecks-migraenemiddel-for-spaendende-i-stort-migraenemarked -
Forskningsdirektør: Lundbeck tættere på middel mod migræne
https://www.proinvestor.com/investornyt/970488/forskningsdirektor-lundbeck-taettere-pa-middel-mod-migraene -
Har Alk-Abello fået (u)berettiget mange
kursklø? https://www.proinvestor.com/boards/112148 -
Lundbeck får hævet kursmålet hos britisk
storbank https://www.proinvestor.com/investornyt/971215/lundbeck-far-haevet-kursmalet-hos-britisk-storbank -
Is Abbott Laboratories Still a Good Dividend Stock to Buy? https://www.proinvestor.com/investornyt/972225/is-abbott-laboratories-still-a-good-dividend-stock-to-buy
-
Is Teladoc Health a Good Stock to Buy Now? https://www.proinvestor.com/investornyt/972223/is-teladoc-health-a-good-stock-to-buy-now
-
Novartis delivers strong sales growth, robust margin expansion and major innovation milestones. Raises FY guidance
25.4.2023 07.00 • GlobeNewswire •
Ad hoc announcement pursuant to Art. 53 LRQ1 sales grew +8% (cc
1
, +3% USD) and core operating income grew +15% (cc, +8% USD)
-
Innovative Medicines (IM) sales grew +7% (cc, +3% USD) and core operating income +18% (cc, +11% USD)
-
IM core margin 38.7%, +360 bps cc, driven by higher sales and productivity programs
-
-
AstraZeneca, Ionis' eplontersen shows sustained benefit on neuropathy impairment, QoL https://firstwordpharma.com/story/5731157?aid=5731157
-
FDA expands approval of AbbVie's Qulipta to chronic migraine https://firstwordpharma.com/story/5729008
-
(Lundbeck er på vej i samme indikation)
-
Mere migræne : IntelGenx Announces FDA Approval of RIZAFILM for the Treatment of Acute Migraine https://firstwordpharma.com/story/5728756
-
Pfizer bags FDA approval for Zavzpret migraine nasal spray https://firstwordpharma.com/story/5714749
-
FDA Grants Accelerated Approval For Biogen's ALS Drug https://www.proinvestor.com/investornyt/973749/fda-grants-accelerated-approval-for-biogens-als-drug
-
Medicinalsektor kritiserer EU-forslag om revision af regulering https://www.proinvestor.com/investornyt/974114/medicinalsektor-kritiserer-eu-forslag-om-revision-af-regulering
-
Novo-topchef ser EU-forslag som "det dummeste jeg har hørt" https://www.proinvestor.com/investornyt/974134/novo-topchef-ser-eu-forslag-som-det-dummeste-jeg-har-hort
-
Nordea hæver kursmålet på Lundbeck We raise our revenue estimates by 1-2% going forward, EBITDA estimates by 2% and EBIT estimates by 3-4% – driven by Rexulti and slightly better operating leverage. Our DCF-derived target price is raised to DKK 44 (41) and we remain buyers of the stock
-
AstraZeneca Q1 Core Profit Rises, Revenue Ex COVID-19 Up 15% At CER; Reiterates FY23 Guidance https://www.proinvestor.com/investornyt/974670/astrazeneca-q1-core-profit-rises-revenue-ex-covid-19-up-15-at-cer-reiterates-fy23-guidance
-
GSK's Respiratory Syncytial Virus Older Adult Vaccine Candidate Gets Positive CHMP Opinion https://www.proinvestor.com/investornyt/974665/gsks-respiratory-syncytial-virus-older-adult-vaccine-candidate-gets-positive-chmp-opinion
-
FDA staff flag concerns over broad use of Lynparza combo in prostate cancer FDA staff flag concerns over broad use of Lynparza combo in prostate cancer
Hello! It looks like you're interested in this conversation, but you don't have an account yet.
Getting fed up of having to scroll through the same posts each visit? When you register for an account, you'll always come back to exactly where you were before, and choose to be notified of new replies (either via email, or push notification). You'll also be able to save bookmarks and upvote posts to show your appreciation to other community members.
With your input, this post could be even better 💗
Tilmeld Log ind